H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of MapLight Therapeutics (MPLT) with a Buy rating and $45 price target MapLight is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, the analyst tells investors in a research note. The firm believes MapLight’s lead candidate could generate peak sales approaching $4B annually if approved in both schizophrenia and Alzheimer’s disease psychosis.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MPLT:
- MapLight Therapeutics completes enrollment in ZEPHYR trial
- MapLight Therapeutics Announces Board Refresh and New Nominees
- MapLight Therapeutics initiated with a Buy at Needham
- Buy Rating on MapLight: Differentiated CNS Pipeline and Undervalued Schizophrenia Opportunity with Upside in Alzheimer’s and Neuropsychiatric Indications
- MapLight Therapeutics initiated with a Buy at TD Cowen